ACCESS Newswire·Jul 1, 2026, 4:05 PM ET

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics granted inducement awards to three newly hired employees on June 30, 2026, under its Inducement Plan adopted in 2018 & amended in 2020 & 2022.
The aggregate awards consist of options to purchase 8,650 shares & restricted stock units (RSUs) for 2,275 shares of common stock.
The option exercise price is set at $122.58, matching the Nasdaq closing price on June 30, 2026.
Options vest over four years, with 25% vesting on the first anniversary of hire & the remainder in equal monthly installments over the subsequent three years.
RSUs vest annually at a rate of one-fourth per share over a four-year period.
The awards were approved by the compensation committee as a material inducement in compliance with Nasdaq Marketplace Rule 5635(c)(4).
ICOTYDE (icotrokinra) launched in the U.S. in March 2026 for moderate-to-severe plaque psoriasis in adults & pediatric patients aged 12+, with Phase 3 trials ongoing for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
An NDA for rusfertide for polycythemia vera is under priority FDA review following Takeda Pharmaceuticals' licensing.
The company's pipeline includes programs targeting IL-17, obesity via dual & triple agonists, hepcidin mimetics, IL-4, & amylin.